Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

Summary

This phase II trial tests how well M1774 works in treating patients with prostate cancer that does not respond to treatment (refractory) and that has a mutation in the gene responsible for making the speckle type BTB/POZ protein (SPOP). M1774 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving M1774 may be able to shrink or stabilize refractory SPOP-mutant prostate cancer.

Timeline

Start

2023-10-16

Primary completion

2027-01-01

Completion

2027-01-01

Drugs

Indications